Latest News
Feb 2010
NovaBiotics scientist to run Edinburgh Marathon for The CF Trust (23rd May)
20/1/10
Clinical development success for NovaBiotics - Life Sciences Scotland News, Issue 48
11/1/10
NovaBiotics attending PepTalk 2010 in San Diego
4/1/10
NovaBiotics prepares to out-license nail product - The Herald
20/11/09
NovaBiotics nears licensing deal for topical antifungal candidate - SCRIP
20/11/09
Initial Phase IIa clinical data for Novexatin® supports Phase I findings
4/11/09
First Phase IIa patients complete trial successfully
3/11/09
NovaBiotics a step closer to licensing - The Scotsman
1/11/09
Enterprise Scotland Magazine - NovaBiotics Article
27/10/09
Bio-Europe 2009 - NovaBiotics' Profile
01/10/09
Novexatin® Phase IIa study commences
09/09/2009
Official launch of the science behind Novexatin® at ICAAC, San Francisco on 13th September 2009
01/09/2009
Positive Phase 1 clinical data for nail fungus treatment, Novexatin®
25/08/2009
Phase 1 Clinical Study for Novexatin® Concludes
21/08/2009
NovaBiotics selected to present data at high profile, international events
06/07/2009
Clinicial trials commencing for NovaBiotics' nail fungus treatment, Novexatin®
01/07/2009
NovaBiotics Reaches Financing Target set for H1 2009
29/05/2009
23/03/2009
NovaBiotics Ltd raise £451 and counting for Red Nose Day 2009!
12/02/2009
Further funding secured in a key year for "clinic-ready" Novabiotics
06/02/2009
NovaBiotics Ltd wins Rising Star Award at the BioIndustry Association Thistle Bioscience Forum
26/01/2009
NovaBiotics to present at the BIA Scotland Thistle Bioscience Showcase 2009
24/11/2008
15/10/2008
Preclinical Development of Novexatin™ Complete
14/10/2008
NovaBiotics attends ICAAC 2008
04/10/2008
New Appointments at NovaBiotics
04/10/2008
Completion of Interim Fundraising
30/09/2008
NovaBiotics is a clinical stage biotechnology company based in Aberdeen and was founded in 2004. Its unique patented peptide anti-infective technology has already demonstrated enhanced efficacy, safety and bioavailability over current and emerging competition as well as the potential for a fast-track route to market and revenue initially through its first application, a topical (brush on) treatment for fungal nail infections (NP213/Novexatin®).
Registered in Scotland No. SC272344. Registered Address: NovaBiotics Ltd, Cruickshank Building, Craibstone, Aberdeen, AB21 9TR, UK
© NovaBiotics Ltd 2009.
All Rights Reserved
Last updated
8 February, 2010
